MRI and PET in the Characterization of Brain Tumors

MRI and PET in the Characterization of Brain Tumors
Sponsored by the SNMMI Brain Imaging Council, Correlative Imaging Council,  and PET Center of Excellence

Thomas A. Hope, MD

Ephraim E. Parent, MD, PhD

Derek. R. Johnson, MD
Igor Yakushev, MD
Maria R. Ponisio, MD
Javier Villanueva-Meyer, MD

Course Summary
Imaging of brain tumors requires the complex correlation between MRI and molecular imaging modalities.  There has been extensive research over the years using various radiopharmaceuticals including FET and FDOPA among other radiotracers, although MRI remains the mainstay of imaging.  With the approval of FDOPA and the potential of using fluciclovine for brain tumor imaging, we are closer than ever to being able to use amino acid radiotracers clinically.  We will review the role and current limitations of MRI in the setting of treatment response for both primary and metastatic tumors.  We will then discuss how amino acid radiotracers can improve lesion characterization, potentially improving patient outcomes.  To inform the discussion, we will have a radiation oncologist discuss how imaging is used in therapy planning. 

1. Examine the limitations of MRI in the evaluation of treatment response for brain tumors.
2. Review how imaging is used to plan radiation therapy.
3. Discuss the additive value of molecular imaging to help MRI overcome its limitations.

CE Information

CE/SAM Credit applications for physicians, pharmacists, physicists and technologists are pending. 
4/29/2021 10:00 AM - 11:30 AM

Register for Another Webinar

Sign In to Register